ORYZON Genomics awarded $270,000 Research Grant to fund IND of its Novel Epigenetic for Alzheimer's Disease
Oryzon Genomics, an epigenetics-based biotechnology company focused on developing therapeutics in oncology and neurodegenerative diseases, today announced that The Alzheimer’s Drug Discovery Foundation (ADDF) has awarded a $270,000 grant to the company for continued development of its molecule ORY-2001, a dual LSD1-MAOB inhibitor, as a new therapeutic approach for Alzheimer’s disease (AD). The ADDF award will fund work to finalize the preclinical toxicological characterization needed to move Oryzon’s LSD1-MAOB dual inhibitor ORY-2001 to clinical stage this year.